Vulva Cancer

An overview of disease, diagnosis and treatment

Vulva Cancer

The vulva is a woman’s external genitalia. It is composed of the skin, connective tissue and fatty tissue surrounding the clitoris and the openings of the vagina and urethra. Cancers often occur in, or on, labia majora or labia minora, and more seldom on the clitoris, or in the Bartholin’s glands on the sides of the vaginal entrance. Vulva cancer is named from the cell type, where the cancer starts.  The most common type is a squamous cell carcinoma, which originates from the cells in the outer layer of the skin in vulva. Other less common types are adenocarcinoma (from glandular tissue), malignant melanoma, and sarcoma. The treatment options for vulvar malignancy are dependent on the tumor type, size, location and possible spread to lymph nodes and/or distant sites in the body.

Epidemiology

The disease mostly affects older women (over 70 years), but it can also be diagnosed in younger women. The cancer may be solitary or multifocal. As the location of the disease implies, the disease and the treatment may cause visible sequelae following treatment.

Symptoms

Vulva cancer can present in various ways, incl. as a red scaling and/or itching flat area, as either a protruding or deep growing tumor, or as a not healing wound.

In early stages, vulva cancer rarely has any symptoms. As the disease progresses, the cancer may develop symptoms incl. palpable swelling/tumor in the area, itching, burning, pain (e.g. during urination), and bleeding.

Reporting any symptoms early to your primary physician is important for detecting vulva cancer in early stage, where the malignancy may be curable.

Causes and Risk Factors

The exact cause of vulva cancer is not known, but several conditions predispose (are risk factors for) developing vulvar malignancy.

  • Infection with Human Papilloma Virus (HPV)
  • HIV infection
  • The autoimmune disease Lichen sclerosis
  • Smoking
  • Family history of malignant melanoma

Diagnosis

The diagnosis of vulva cancer can be an incidental finding at a routine gynaecological examination, or be based on the development of symptoms.  If cancerous tissue is suspected in the vulva, tissue samples (biopsies) must be taken and send for histological examination, to secure a diagnosis incl. the exact tumor type. 

A thorough gynaecological examination under general anesthesia is sometimes necessary, to sufficiently examine a patient and determine, if surgery is feasible.

Radiologic examination is performed to determine the extent of the disease, and possible spread to lymph nodes/distant organs. Scanning modalities can be PET/CT, CT and/or MRI. If involvement of the urethra or anus/rectum is suspected, a cystoscopy and/or ano/rectoscopy can also be performed.

To determine the most appropiate treatment plan for the patient, an exact diagnosis is warranted, based on abovementioned examinations and histological results.

Vulva Cancer

Squamous cell carcinoma

This is the most common histological type of vulva cancer. It develops in the squamous cells in the skin lining the vulva. If not treated, it may spread superficially or grow deeper into nearby tissue incl. anal region and urethra. The cancer can spread to lymph nodes and distant sites incl. bones, lungs, and liver.

Melanoma

Malignant Melanoma may be diagnosed on the skin in the vulva region. Treatment for this type of cancer is different from the treatment described below for the squamous cell carcinoma in vulva.

Examination Methods

Biopsy

A biopsy is a small tissue sample from suspicious areas/tumor. Often several biopsies are taken to thoroughly investigate a tumor and surrounding tissue. Biopsies are send for histological  examination by a pathologist, and are warranted to make a definite diagnosis of cancer incl. the type.

If a biopsy shows invasive vulva cancer, the patient must be referred to a specialized gynaecologic oncologist department, where there is expertise in treating this type of cancer.

Computed Tomography (CT) scan

A CT scan visualizes the inside of the body using x-rays from different angles. Intravenous infusion of CT contrast fluid enhances the details on the CT-scan, and aids the radiologist in distinguishing normal from pathologic tissue. 

On a CT scan the tumor’s size can be measured, and any enlarged lymhp nodes or pathologic tumors in other organs be shown.

Magnetic Resonance Imagin
(MRI) scan

A MRI scan uses magnetic fields to produce detailed images of the body. Often the tumor size is more precisely measured on a MRI scan, instead of on a CT or PET/CT scan. MRI is also valuable to detect invasion/growth in to neighboring organs.

Endoscopy

An endoscopy allows the doctor to see inside the body via a thin, flexible tube with light in the end. Hereby the doctor can examine e.g. the bladder (cystoscope) or the rectum (rectoscope).

Colposcopy

Vulvar colposcopy is performed by specialist gynaecologists. The colposcopy is an instrument (microscope), which the doctor uses to inspect for abnormal tissue, tumors and bleeding in the vulva.

In case of irregular/suspicious area(s), the doctor will perform biopsies for histological examination. 

Positron emission tomography (PET) or PET-CT scan

A PET scan is usually combined with a CT scan (see above), and the combined scan is called a PET-CT scan. It can provide additional information regarding a cancer, than only a CT scan can do.

For a PET scan a small amount of a radioactive sugar substance is injected intravenously into the patient before the scan. The radioactive substance is taken up by the most energetic cells in the body, which includes cancerous cells.

A PET scanner then detects the distribution of this substance in the body, and by adding these data to a CT scan, the combined examination can with great details demonstrate size, location, extent and possible spread of the cancer. 

This is very useful information for the doctor to have, before determining the optimal treatment strategi for a patient.

Treatment Options

Radiation therapy

Radiation therapy is an option for treating vulva cancer, and is used for irresectabel cases with or without spread to lymph nodes. 

Surgery may be performed more than once on a patient, but if radicality is not obtainable, then radiation therapy is a better option, as it may be curable in selected cases.

It may also be given after surgery to reduce the risc of recurrence.

Radiation therapy uses high-powered energy beams (usually fotons) to destroy and kill cancer cells. The cancerous tissue (tumor) is irradiated from the outside by “external beam radiation therapy”.

During radiation treatment care is taken to protect the surrounding normal tissue such as bladder, and rectum etc. However, it is often unavoidable that a limited dose affects the surrounding tissue, and consequentially results in side effects of varying degree. 

For vulva cancer these will often be redness, desquamation, and ulcers in vulva, pain, urinary problems, diarrhea, inflammation of the mucous membranes in the vagina, bladder, and rectum. Development of scar-tissue in the vulva area (fibrosis), and swelling af the leg(s) due to lymphoedema is common. 

Discuss the risks and possible treatment options with your radiation oncologist prior to commencing your treatment.

Surgery

Surgery is the treatment of choice for early stage, small, and localized vulva cancer. The surgeon performs a local excision of the cancerous tissue with a margin of healthy tissue surrounding it. Lymph nodes may be removed also.

Vulvectomy is a more comprehensive surgical procedure, used for more advanced stages of vulva cancer. In a  vulvectomy all or part of the vulva is resected. 

A number of women who have undergone aggressive vulvectomy, may need reconstructive surgery(ies) incl. specialized plastic surgery with skin grafts performed by skilled surgeons.

Chemotherapy

Chemotherapy intravenously may be a treatment option for women with previously irradiated, recurrent or disseminated vulva cancer. 

It can be prescribed together with radiation therapy to increase the effectiveness of the radiation. 

Making decisions about your care

The choice of therapy for your cancer is an individual decision, and many factors are taken in to consideration, when your doctor(s) discuss the best option(s) with you. These include the type, size and location/spread of the tumor, as well as your age and general health status. 

We recommend, that you have a thorough discussion with your doctor(s) about the results upon your diagnosis, the treatment-plan and your chances of recovery (e.g. prognosis).

You are encouraged to include family and/or friends for participation in doctors appointments etc. for improving your/their understanding and remembrance of relevant information, as well as for emotional and physical support during appointments and treatments. 

Your doctor can give a detailed explanation of the various therapy options, and has knowledge of the possibility to participate in a clinical trial. Each patient is different and so is their wish upon information needed/wanted prior to making important decisions. 

Well designed and conducted clinical trials are essential to determine the effectiveness of a promising new drug or intervention. Many gynaecologic oncology departments have studies open for inclusion during the course of your cancer treatment. Talk to your doctor(s) about your thoughts regarding possible inclusion in a clinical trial now or in the future.

                                                                                                               (References; www.DGCG.DK, Kræft Klinik og sygepleje, FADL’s forlag 2019) 

Author: Kristine Madsen, MD, Deputy Medical Director NSGO-CTU

We use cookies to give you the best experience on our website. You can find out more about which cookies we use:

Cookie information Jeg accepterer
Cookie indstillinger
Nødvendige

Required cookies help make the site usable by enabling basic features such as Slide functions, and ensure full access to all pages on our site. The website does not work optimally without these cookies. We have considered these as paid and are therefore stored without prior consent.

Expires
session
Name
PHPSESSID
Data processor
System
Purpose
Bruges til at holde styr op brugrens session
Expires
1 year
Name
wordpress_[hash]
Data processor
System
Purpose
Ved login bruger WordPress wordpress_[hash] cookien til at gemme dine godkendelsesoplysninger.
Expires
1 year
Name
wordpress_logged_in_[hash]
Data processor
System
Purpose
Efter login indstiller WordPress wordpress_logged_in_[hash] cookien, der angiver, hvornår du er logget ind, og hvem du er, til de fleste grænsefladebrug.
Expires
1 year
Name
wp-settings-{time}-[UID]
Data processor
System
Purpose
Dette bruges til at tilpasse din visning af admin interface, og muligvis også hovedwebstedets interface.
Expires
1 year
Name
comment_author_{HASH}
Data processor
System
Purpose
Når besøgende kommenterer din blog, får de også gemt cookies på deres computer.
Expires
1 year
Name
comment_author_email_{HASH}
Data processor
System
Purpose
Når besøgende kommenterer din blog, får de også gemt cookies på deres computer.
Expires
1 year
Name
comment_author_url_{HASH}
Data processor
System
Purpose
Når besøgende kommenterer din blog, får de også gemt cookies på deres computer.
Expires
session
Name
woocommerce_cart_hash
Data processor
System
Purpose
Hjælper WooCommerce med at afgøre, hvornår vognens indhold/data ændres.
Expires
session
Name
woocommerce_items_in_cart
Data processor
System
Purpose
Hjælper WooCommerce med at afgøre, hvornår vognens indhold/data ændres.
Expires
2 dage
Name
wp_woocommerce_session_
Data processor
System
Purpose
Indeholder en unik kode for hver kunde, så den ved, hvor han kan finde vogndataene i databasen for hver kunde.
Expires
session
Name
woocommerce_recently_viewed
Data processor
System
Purpose
Giver widgeten Seneste viste produkter.
Expires
session
Name
store_notice[notice id]
Data processor
System
Purpose
Tillader kunder at afvise butiksmeddelelsen.
Expires
1 year
Name
cookie_settings
Data processor
System
Purpose
Bruges til at angive dine cookieindstillinger.
Luk info
Jeg accepterer

Privacy Policy for NSGO

NSGO treats personal information and complies with the laws and principles of good data processing practices. Therefore, we have adopted this Privacy Policy, which briefly describes how we treat personal information, so legal and transparent processing is ensured.

We are responsible for processing your personal information:

NSGO is the data controller and you can always contact the organization’s data protection officer:

Mansoor Raza Mirza

Nordic Society of Gynecologic Oncology – Clinical Trial Unit
Copenhagen University Hospital
Department of Oncology, 9431
Blegdamsvej 60
DK-2100 Copenhagen
Office phone: +45 35 45 33 78
fax: +45 3545 2898
Mansoor.Raza.Mirza@regionh.dk.

We treat the following personal information about members:

  • General personal information: For example, contact information such as name, work address, work phone number, private phone number, date of birth, email address, country, work title, date of membership, date of membership termination and cv in relation to membership application. Parts of credit card number via Epay and, if applicable, Bank account number for reimbursement purposes. When applicable, Board Members may be asked to give NSGO copies of other personal documents (for example passport or tax bill) in relation to the Danish Laundering Act.
  • Other information: For example, positions of trust, board membership and other duties in relation to the organization.

We collect personal information from:

Usually we will get the information from you, when you register to become a member of NSGO and when you apply for reimbursements or pay your membership fee

The organization’s legal basis to process personal information:

  • That we as an organization have a (legitimate) interest in processing your information
  • That it is necessary for us to fulfill an agreement with you
  • You have agreed that we can process your information via becoming a member of the

The purpose of processing personal information:

  • That we can run the organization’s activities, including planning, implementing and following up on them
  • To invite to vote for Board and President Elect elections
  • To distribute newsletters
  • To comply with legislation
  • To deliver services, in the form of the possibility to participate in the Annual Meeting, Investigator Meeting and if applicable Strategic Meetings, Board Meetings, Scientific Committee Meetings, Foundation Meetings.
  • To notify members about other Gynecologic Cancer Managing your relationship with the organization
  • To handle your membership rights
  • For you to fulfill your obligations as a member of the organization, including paying the membership fee, etc.
  • Being able to display situation images from a specific event in the organization for instance from NSGO Annual Meetings
  • To maintain historical value data for statistics and the like

Consent:

When you become a member, we have a legal basis to process your personal information for the (legitimate) interest of the organization. However, it may happen that we judge it necessary to obtain your written consent for other purposes. In that case you will have the opportunity to voluntarily agree, and you may withdraw it at any time by notifying us.

Dispatch of your personal information:

We do not disclose information about you to anyone outside the organization without your consent, however, it should be noted, that if you e.g. accept an invitation to a meeting, your personal information might be forwarded to the meeting location or the meeting organizer. Only personal information relevant for the 3rd party will be disclosed in these circumstances.

Storing and deleting your personal information:

For historical reasons and as your details might be saved in old attendance lists, email correspondence and minutes from meetings, we cannot promise that all personal information about you will be deleted, if you terminate your membership.

Your rights:

You have a number of rights via the General Data Protection Regulation (GDPR):

  • The Right to Information (to be informed what information we process about you)
  • The Right to Rectification (to have false information about you corrected)
  • The Right to Restriction of processing (under certain conditions, to have the processing of your data restricted)
  • The Right to Object (to object to your information being used for wrong purposes)

You may make use of your rights by contacting us. If you submit a request to have your personal information corrected or deleted, we will investigate whether the conditions are met and, in that case, make changes or deletions as soon as possible and, if applicable, also notify our data processors to do so.

You can file a complaint with the supervisory authorities – The Danish ‘Datatilsynet’ – About processing your personal information (www.datatilsynet.dk).

Revision of Privacy Policy:

We reserve the right to change the organization’s privacy policy. When we change privacy policy, we also change the date and version number at the bottom of this document. In case of significant changes, you will receive a notification.

The current privacy policy is always available on our website.

Practice Areas

Newsletter

Sign up to our newsletter

Privacy Policy for NSGO-CTU

NSGO-CTU treats personal information and complies with the laws and principles of good data
processing practices. Therefore, we have adopted this Privacy Policy, which briefly describes how we treat personal information, so legal and transparent processing is ensured.

We are responsible for processing your personal information:

NSGO-CTU is the data controller and you can contact the organization’s data protection officer:

Mansoor Raza Mirza

Nordic Society of Gynecologic Oncology – Clinical Trial Unit
Copenhagen University Hospital
Department of Oncology, 9431
Blegdamsvej 60
DK-2100 Copenhagen
Office phone: +45 35 45 33 78
fax: +45 3545 2898
Mansoor.Raza.Mirza@regionh.dk.

We treat the following personal information about personnel participating in NSGO-CTU trials:
• General personal information: For example; contact information such as name, work
address, work phone number, date of birth, email address, country, work title, date of start
of participation and termination in a trial and, if applicable, CV, GCP certificates, records of
training and other qualification data.
• If applicable, financial disclosure forms and/or Bank account number for reimbursement
purposes.

We collect personal information from:
• We will ask you to provide us the information yourself, when you in decide to take part
in NSGO-CTU trials.
The organization’s legal basis to process personal information:
• That we as an organization have a (legitimate) interest in processing your information, for
example to secure your qualifications in handling the care of the participants in a trial.
• That it is necessary for us to fulfill an agreement with your employer
• You have agreed that we can process your information via signing the delegation log.
The purpose of processing personal information:
• The participation of an investigator or of other individuals in a clinical trial which is being
conducted according to the principals governing clinical research as set out in the
Declaration of Helsinki and with the acceptance of all involved Regulatory Health
Authorities and involved Ethical Committees, requires collection, recording, storage,
transfer and/or other use of personal data (personal data processing).
• Communicate regarding studies.
• To handle payments and reimbursements.
• To comply with legislation.
• To deliver services, in the form of the possibility to participate in the Annual Meeting,
Investigator Meeting.
• To be able to give you access to IT systems, databases, eCRFs etc. related to the functioning
of each individual trial.

Consent:
When you decide to take part in a NSGO-CTU trial NSGO-CTU either makes a contract with you or
your employer where terms and conditions are described, or if you put your name on the
Delegation Log of a trial, you agree to the information described in this Privacy Policy.
However, it may happen that we judge it necessary to obtain your written consent for other
purposes. In that case you will have the opportunity to voluntarily agree, and you may withdraw it
at any time by notifying us.
Be aware that there are legal bases for certain forms of processing of your data for the abovementioned purposes and that your consent is the only legal basis for other forms of processing.

Dispatch of your personal information:
Depending on your role in a trial, your personal information might be shared with personnel at
other sites, monitors, group staff in other countries, NSGO-CTU office staff, members of NSGO,
CRO staff, Ethics Committees and Competent Authorities, both in Europe, but also in countries
outside the European Economic Area (for example the US). If your data (personal information) has
been transferred, they will be subject to the data protection legislation of the respective country,
also if a less severe data protection law should exist.
We do not disclose information about you to anyone outside the organization without the above
consent, however, it should be noted, that if you e.g. accept an invitation to a meeting, your
personal information might be forwarded to the meeting location or the meeting organizer. Only
personal information relevant for the 3rd party will be disclosed in these circumstances.
Furthermore, your data can be transmitted to public databases for registration, as well as
publication of a trial and your data can be stored and published in those databases.
Storing and deleting your personal information:
For historical reasons and as your details might be saved in old attendance lists, email
correspondence and minutes from meetings, we cannot promise that all personal information
about you will be deleted, when you end your participation in a study. In general, all information
about a trial is deleted at least 20 years after end of study.

Your rights:
You have a number of rights via the General Data Protection Regulation (GDPR):
• The Right to Information (to be informed what information we process about you)
• The Right of Access (to get a print of the information we process about you)
• The Right to Rectification (to have false information about you corrected)
• The Right to Erasure (to delete information we process about you, however, information
already received cannot be deleted)
• The Right to Restriction of processing (under certain conditions, to have the processing of
your data restricted)
• The Right to Object (to object to your information being used for wrong purposes)

You may make use of your rights by contacting us, however, the legality of the processing carried out
prior to e.g., a withdrawal will not be affected. If you submit a request to have your personal
information corrected or deleted, we will investigate whether the conditions are met and, in that
case, make changes or deletions as soon as possible and, if applicable, also notify our data
processors to do so.

If you do not believe that NSGO-CTU handles your data correctly, you can file a complaint with the
supervisory authorities – The Danish ‘Datatilsynet’ – About processing your personal information
(www.datatilsynet.dk).

Revision of Privacy Policy:
We reserve the right to change the organization’s privacy policy. When we change privacy policy,
we also change the date and version number at the bottom of this document. In case of significant
changes, you will receive a notification.

The current privacy policy for NSGO-CTU is always available on our website.

Practice Areas

Newsletter

Sign up to our newsletter

Found Something Interesting?

Powered By EmbedPress